Although single-agent trastuzumab exerts some antitumor activity, the highest clinical benefit is derived when trastuzumab is combined with chemotherapy [1]–[5] HER2 testing has become routine practice in every patient with breast cancer since the benefit of trastuzumab is limited to patients with HER-2 positive breast cancer. Here, ERBB2 is linked to breast cancer.